A promotion with a date attached
SuperHealthy Rx lists semaglutide at $85 and tirzepatide at $135 per month on the retrieved GLP-1 offer. The page still uses Labor Day sale wording, although our check occurred October 5, 2026. Confirm the live checkout terms and ask whether the amount applies beyond the initial purchase. We do not infer an expiry date from the seasonal heading.
What the service advertises together
The bundle describes clinician review, compounded medication and shipping without a separate membership charge. Automatic refills are presented as optional. A reader considering ongoing care should establish how that option is selected, where the next charge is shown and how questions reach the clinical team.
Keep the care route visible
The offer identifies an MD Integrations network and describes U.S. licensed pharmacies. Ask who will actually prescribe and dispense for your order. A general description of a network cannot tell you which organization to call about a particular label, delivery or treatment concern.
Compounded medicines are not FDA-approved. The decision about whether such a preparation addresses an individual medical need requires a licensed clinician. A lower advertised price does not answer that question, and clinical-trial results for a branded medicine do not establish this service's own patient outcomes.
Our role in this comparison
SuperHealthy appears second because the publisher selected that promotional placement. Links may earn compensation. We have not ordered medication, assessed pharmacy operations or tested the response to a follow-up request. This profile asks the practical questions that may remain once the sale heading is no longer the most important part of the page: the next charge, the responsible professionals and the route back into care.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- SuperHealthy Rx — GLP-1 offerProvider promotion
- FDA — compounding questions and answersRegulatory context
- FDA — concerns with unapproved GLP-1 drugsSafety and product context